Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04644237
Title Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)
Acronym DESTINY-LUNG02
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | ITA | FRA | ESP | CAN | AUS

Additional content available in CKB BOOST